# LEO Pharma clinical trials: 225 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 225 trials with LEO Pharma as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by LEO Pharma: 225 rows for $11.25, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/leo-pharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 225
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 225, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 22, 2026 | NCT07603193 | Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream | LEO Pharma | Observational | Enrolling by invitation | Chronic Hand Eczema (CHE) | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07603193) |
| January 13, 2026 | NCT07335588 | A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus | LEO Pharma | Phase 3 | Recruiting | Lichen Sclerosus | 552 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07335588) |
| June 10, 2025 | NCT07013201 | A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar... | LEO Pharma | Phase 2 | Recruiting | Palmoplantar Pustulosis | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07013201) |
| October 3, 2024 | NCT06624670 | A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum | LEO Pharma | Phase 3 | Recruiting | Pyoderma Gangrenosum | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06624670) |
| June 6, 2024 | NCT06444867 | A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968 | LEO Pharma | Phase 1 | Completed | Joint Pain, Gout Flares, Joint Inflammation | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06444867) |
| March 15, 2024 | NCT06311682 | A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With... | LEO Pharma | Phase 3 | Recruiting | Atopic Dermatitis | 195 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06311682) |
| August 28, 2023 | NCT06013969 | A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares | LEO Pharma | Phase 4 | Completed | Generalized Pustular Psoriasis | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06013969) |
| August 22, 2023 | NCT06004050 | A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe... | LEO Pharma | Phase 3 | Completed | Chronic Hand Eczema | 362 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06004050) |
| July 24, 2023 | NCT05958407 | A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are... | LEO Pharma | Phase 3 | Completed | Atopic Dermatitis, Atopic Hand Eczema | 235 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05958407) |
| June 28, 2023 | NCT05923099 | A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis | LEO Pharma | Phase 2 | Completed | Atopic Dermatitis | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05923099) |
| June 26, 2023 | NCT05919082 | A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque... | LEO Pharma | Phase 3 | Completed | Stable Plaque Psoriasis | 604 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05919082) |
| January 12, 2023 | NCT05682352 | Investigating the Safety of LEO 158968 in Healthy Volunteers | LEO Pharma | Phase 1 | Completed | Healthy | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05682352) |
| August 3, 2022 | NCT05486117 | Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema | LEO Pharma | Phase 1 | Completed | Chronic Hand Eczema | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05486117) |
| July 22, 2022 | NCT05470114 | A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD | LEO Pharma | Phase 2 | Completed | Atopic Dermatitis | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05470114) |
| May 24, 2022 | NCT05388760 | Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) | LEO Pharma | Phase 2 | Completed | Atopic Dermatitis | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05388760) |
| May 2, 2022 | NCT05355818 | Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema | LEO Pharma | Phase 3 | Completed | Chronic Hand Eczema | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05355818) |
| April 18, 2022 | NCT05332366 | A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal... | LEO Pharma | Phase 2 | Completed | Frontal Fibrosing Alopecia | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05332366) |
| March 25, 2022 | NCT05295732 | The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis | LEO Pharma | Phase 3 | Completed | Ichthyosis | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05295732) |
| February 28, 2022 | NCT05259722 | A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult... | LEO Pharma | Phase 3 | Completed | Chronic Hand Eczema | 513 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05259722) |
| January 18, 2022 | NCT05194540 | Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis... | LEO Pharma | Phase 3 | Completed | Atopic Dermatitis | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05194540) |
| October 29, 2021 | NCT05099133 | A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects | LEO Pharma | Phase 1 | Completed | Atopic Dermatitis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05099133) |
| September 20, 2021 | NCT05050279 | A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People | LEO Pharma | Early phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05050279) |
| July 2, 2021 | NCT04949841 | Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials | LEO Pharma | Phase 3 | Completed | Chronic Hand Eczema | 801 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04949841) |
| June 10, 2021 | NCT04922021 | An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. | LEO Pharma | Phase 2 | Completed | Atopic Dermatitis | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04922021) |
| May 12, 2021 | NCT04883333 | A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults | LEO Pharma | Phase 1 | Completed | Healthy | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04883333) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 68 |
| Phase 1/2 | 6 |
| Phase 2 | 54 |
| Phase 3 | 54 |
| Phase 4 | 15 |
| Not applicable | 2 |
| Observational | 25 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 202 |
| Terminated | 15 |
| Recruiting | 4 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dermatitis, Atopic | 36 |
| Keratosis, Actinic | 31 |
| Psoriasis | 12 |
| Rosacea | 8 |
| Neoplasms | 5 |
| Skin and Connective Tissue Diseases | 4 |
| Venous Thromboembolism | 3 |
| Eczema | 3 |
| Impetigo | 3 |
| Acne Vulgaris | 3 |
| Venous Thrombosis | 3 |
| Multiple Myeloma | 2 |
| Alopecia Areata | 2 |
| Liver Neoplasms | 2 |
| Carcinoma | 2 |
| Connective Tissue Diseases | 1 |
| Hyperparathyroidism, Secondary | 1 |
| Plaque, Amyloid | 1 |
| Lupus Erythematosus, Discoid | 1 |
| Dermatitis | 1 |
| Skin Diseases | 1 |
| Acute Lung Injury | 1 |
| Respiratory Distress Syndrome | 1 |
| Thromboembolism | 1 |
| Hemostatic Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Wine bars in the United States](https://specstream.ai/data/businesses/wine-bars/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Uniform stores in the United States](https://specstream.ai/data/businesses/uniform-stores/united-states)
- [Tools wholesalers in the United States](https://specstream.ai/data/businesses/tools-wholesalers/united-states)
- [Taiwanese restaurants in the United States](https://specstream.ai/data/businesses/taiwanese-restaurants/united-states)
- [Spine surgery practices in the United States](https://specstream.ai/data/businesses/spine-surgery-practices/united-states)
